The following LIMR-developed IP and technologies are available for licensing. To learn more, please contact LIMR at 484.476.8000 or email info@limr.org.

Download the LIMR inventions and innovations booklet (PDF)

Cancer

Targeted nano-carrier therapeutics to treat drug-resistant cancers

Lead investigator: Janet Sawicki, PhD

Taking a new precision medicine approach, LIMR researchers developed a safe and effective nanocarrier-based therapy that specifically targets ovarian tumor cells and blocks a central mechanism of drug resistance (siHuR-3DNA). Preclinical proof of concept suggests that targeting this mechanism via this nanocarrier agent may offer safe and effective treatment of a variety of solid tumors exhibiting drug resistance.

Small molecule inhibitors and poisons of polyamine transport

Lead investigator: Susan Gilmour, PhD

Work by two leaders in the field, including LIMR Deputy Director Susan Gilmour, PhD, led to the discovery of drug-based strategies to target the upregulated polyamine-transport system in tumors. In preclinical studies, these strategies safely and effectively kill tumor cells, either directly, with polyamine-conjugated cytotoxic drugs, or indirectly, by reversing local tumoral immunosuppression and activating effective anti-tumor immunity.

New uses of IDO inhibitors: enhance molecular targeted cancer drug therapy

Lead investigator: Alexander Muller, PhD

Dr. Alexander Muller and his team defined a new use for IDO1 inhibitors to ablate tumor vasculature, including in combination with other anti-angiogenic drugs or other anti-cancer modalities where leveraging anti-angiogenesis is beneficial.

Blood test to predict delayed nausea

Lead investigator: U. Margaretha Wallon, PhD

LIMR's blood-based assay, termed the MyNauseaRisk test, reliably predicts which cancer patients will experience delayed-onset nausea after chemotherapy, even before the chemotherapy is administered.

Combination small molecule inhibitors of IDO/TDO enzymes

Lead investigators: Alexander J. Muller, PhD and George C. Prendergast, PhD

LIMR scientists synthesized second-generation “combi” or “pan” inhibitors that block the catalytic activity of the IDO1, IDO2 and/or TDO2 enzymes.


Autoimmune disease

Anti-RhoB antibodies: broad spectrum treatment for autoimmune disease

Lead investigators: Lisa Laury-Kleintop, PhD and Laura-Mandik-Nayak, PhD

Building on long-standing studies of the disease-promoting small GTPase RhoB, including in selectively driving production of autoantibodies, LIMR scientists developed a cell-permeable anti-RhoB antibody that exhibits therapeutic efficacy in preclinical models of rheumatoid arthritis, lupus and diabetes.

Anti-IDO2 antibodies: new treatment for rheumatoid arthritis and lupus

Lead investigator: Laura Mandik-Nayak, PhD and Lisa Laury-Kleintop, PhD

The immunomodulatory enzyme IDO2, discovered by LIMR scientists, has been identified as an essential mediator of autoimmune disease.


Gastrointestinal

Blood test to distinguish inflammatory bowel disease from inflammatory bowel syndrome

Lead investigator: Thomas Stamato, PhD

With no well-established standards to accurately diagnose IBD, there is a need for biomarkers that are cost-effective, rapid and provide insight into individual disease complexity and biology. In addressing the need for a non-invasive assessment of IBD in patients presenting with IBS, LIMR scientists have developed a blood test that may make this determination as an aid to improving personalized care.

Anti-Bin1 antibodies: new treatment for inflammatory bowel disease

Lead investigator: Sunil Thomas, PhD

Building on their expertise in tissue barrier functions of the GI tract, LIMR scientists developed an antibody-based therapy that inactivates Bin1, a molecule that facilitates gut inflammation in the setting of IBD.


Infectious diseases

Anti-rabies human monoclonal antibody

Lead investigator: Scott Dessain, PhD, MD

LIMR cloned six human monoclonal antibodies (huMabs) from individuals infected with rabies, and in preclinical studies efficiently cleared the infection. These huMabs offer an opportunity for a novel passive vaccine to clear the rabies virus in infected patients.

Diagnostics and vaccines for Lyme disease

Lead investigator: Sunil Thomas, PhD

Researchers synthesized peptides corresponding to the epitopes of the antigenic proteins of Borrelia burgdorferi, the bacterial species responsible for Lyme disease. These peptides could be used in diagnostics and vaccines to protect against Lyme disease.

New approach for drug-resistant topical infections

Lead investigators: George C. Prendergast, PhD, and Melvin Reichman, PhD

Building on concepts developed at LIMR to treat cancer by relieving immunosuppression in the local tumor microenvironment, our researchers have designed an antimicrobial formulation to treat infections by relieving immune barriers imposed by the local microbial ecology in which the infectious agent is embedded.

Anti-amlyoid antibodies: clearing drug-resistant bacteria by targeting the Curli amyloid

Lead investigator: Scott Dessain, PhD, MD

LIMR generated a unique patient-derived huMab that recognizes a universal structural feature present in all amyloid proteins in nature. This finding offers a route for prevention and clearance of drug-resistant bacteria on clinical tubing or device surfaces.


Monoclonal antibody cloning

On-cell antibody display from hybridoma cells

Lead investigator: Scott Dessain, MD, PhD

The Center for Human Antibody Technology (CHAT) is a facility at LIMR that uses a powerful human antibody cloning platform technology developed by Dr. Scott Dessain. The On-Cell Monoclonal Antibody Display System provides biotechnology companies with the ability to clone the broadest array of medicinal candidates from patients with a desired clinical experience.


Neurological disorders

Anti-amyloid antibodies: treatment for amyloidosis

Lead investigator: Scott Dessain, PhD, MD

LIMR scientists generated a unique patient-derived human monoclonal antibody (huMab) that recognizes a common structural feature of all mammalian and bacterial amyloid proteins.

Anti-Bin1 antibodies: treatment for Alzheimer's disease

Lead investigators: Sunil Thomas, PhD, James Mullin, PhD, and George C. Prendergast, PhD

A cell-permeable anti-Bin1 antibody, developed by LIMR scientists as a strategy to blunt Bin1’s pathogenic function in inflammatory bowel disease, was found to exert anti-tau effects in cell culture and animals. Anti-Bin1 may offer a novel tractable target to limit the development or progression of Alzheimer’s disease pathophysiology in patients.

Anti-NMDAR antibodies: diagnostic agent for autoimmune brain encephalitis

Lead investigator: Scott Dessain, PhD, MD

LIMR’s human monoclonal antibody can detect membrane-bound forms of the NMDA receptor, thus enabling clinicians to reliably diagnose the autoimmune disease anti-NMDA receptor encephalitis, a serious psychiatric disorder.


Ocular diseases

New uses of IDO inhibitors: treatment for diabetic retinopathy and macular degeneration

Lead investigators: Lisa Laury-Kleintop, PhD, and Alexander J. Muller, PhD

LIMR scientists defined a new use for IDO inhibitors to treat retinopathies that are driven by formation of pathogenic blood vessels. This new use expands clinical applications for IDO inhibitors as medicines in ophthalmology.

Anti RhoB antibodies: broad spectrum retinopathy treatment

Lead investigators: Lisa Laury-Kleintop, PhD, and Alexander Muller, PhD

LIMR’s anti-RhoB technology addresses resistance to anti-VEGF modalities and targets only pathogenic neovascularization, while sparing normal retinal revascularization.


Reagents

CellCountEZ: rapid assay to measure eukaryotic cell growth and viability

Lead investigator: Iraimoudi S. Ayene, PhD

CellCountEZ, a rapid laboratory test to accurately measure relative cell numbers in tissue culture, is superior to other common tests. It is highly linear to the greatest cell densities achievable, but does not compromise cell viability itself, enabling longitudinal measurements from large bioreactor cell cultures.

ThiOx test: rapid assay to measure thiol antioxidant capacity in cells and tissues

Lead investigators: Iraimoudi S. Ayene, PhD, and U. Margaretha Wallon, PhD

LIMR’s ThiOX test addresses the need for a rapid test to monitor thiol oxidative stress in live cells and tissues.